相关实验视频

Updated: Jul 9, 2026

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

脑瘤中短期与长期 levetiracetam (LIBRA) 的研究方案:一个第三阶段随机对照试验

Archya Dasgupta^1,2, Shakthivel Mani^3,4, Abhishek Chatterjee^3,4

¹Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. archya1010@gmail.com.

|May 21, 2025

概括

这项研究将短期与标准的长期 levetiracetam 对脑瘤患者的控制进行比较. 较短的 levetiracetam 持续时间可能会减少副作用并改善生活质量.

科学领域:

神经瘤学神经瘤学
临床试验临床试验
药理学药理学是指药理学的学科.

背景情况:

发作是脑瘤患者常见的并发症,严重影响他们的生活质量,增加医疗费用.
列维是标准的抗发作药物 (ASM),通常在手术后的2-3年内被处方,尽管治疗后发作发病率很低.
在这个人群中使用ASM的最佳持续时间仍未确定,需要进一步研究.

研究的目的:

为了比较较短的 levetiracetam 治疗方案的疗效和安全性,与在患有原发性脑瘤和发作史的患者中标准的长期治疗方案进行比较.
为ASM使用的最佳持续时间提供1级证据,旨在减少药物使用和神经毒性.

主要方法:

一个随机对照的非劣势性试验,涉及成人患者 (18岁以上) 患有新诊断的脑上瘤 (不包括转移) 和史.
在手术后1年内,在6个月的 levetiracetam 单疗中控制发作的患者将随机 (1:1) 分配为标准长疗程 (额外2年) 或实验性短疗程 (缓和和停止) 的 levetiracetam.
主要终点是2年无生存期 (SFS);次要终点包括影响,生活质量,无进展生存期 (PFS) 和整体生存期 (OS).

主要成果:

该研究旨在招募604名患者,以检测8%的非劣势率,以80%的功率为两年无生存率.
统计分析将比较两个治疗臂之间的初级终点 (2年SFS) 和二次终点.

结论:

这项试验将确定关于在原发性脑中使用抗发作药物的最佳持续时间的明确证据.
成功证明短期治疗方案的非劣势性可能会导致减少药物使用,降低神经毒性,提高生活质量和优化医疗保健资源配置.

关键词:

抗药可以使用.大脑瘤是什么?质瘤是一种质瘤.莱维泰拉塞坦 (Levethiracetam) 是一种发作在发作.

更多相关视频

Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy

Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy

Published on: May 3, 2019

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...